Acorda Therapeutics gets grant for sustained release 4-aminopyridine tablets for neurological disorders

Discover Acorda Therapeutics' innovative patent for sustained release 4-aminopyridine tablets, designed for effective once-daily oral administration.

Aug 23, 2024 - 04:00

Discover Acorda Therapeutics' innovative patent for sustained release 4-aminopyridine tablets, designed for effective once-daily oral administration.

Read the original article

Tags:

Previous Article

Aquestive Therapeutics gets grant for enhanced pharmaceutical compositions for a...

Lyra Therapeutics gets grant for coated scaffold for treating chronic sinusitis

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Risk adjusted net present value: What is the current va...

Apr 17, 2024

STAT+: Pharmalittle: Supreme Court halts Purdue bankruptcy plan; what to know about compounded obesity drugs

STAT+: Pharmalittle: Supreme Court halts Purdue bankrup...

Aug 11, 2023

STAT+: Eisai executive who helped lead development of Alzheimer’s drug to retire

STAT+: Eisai executive who helped lead development of A...

Jul 12, 2023